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A series of novel (4-amino-2-(aryl/alkylamino)thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl)methanone compounds have 
been synthesized. They have been characterized by elemental analysis, IR, 1H and 13C NMR and mass spectral techniques. 
All the synthesized compounds have been screened for their antibacterial potential and show significant antibacterial 
activity. Among these (4-amino-2-(4-chlorophenyl)amino)thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl)methanone is more 
active. Moreover, the compound 3d shows promising antioxidant activity activity. The compounds have been further 
evaluated for their potential for DNA cleavage and two compounds completely cleaved DNA. Two of the compounds have 
been evaluated for their anti-proliferative activity against breast cancer cell lines. The IC50 value of the compound (4-amino-
2-(4-chlorophenyl)amino)thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl)methanone against the cell line MCF-7 is found to be 
10 µg/mL. Four compounds have been docked towards 5077 receptor protein. Molecular docking shows very good 
interaction with protein. In this (4-amino-2-(4-methoxyphenyl)amino)thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl)methanone 
has the highest binding interaction with the protein. 
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Marine algae are one of the richest sources of known 
and novel bioactive compounds. Several of these 
unique compounds have been shown to have 
pharmacological activity against many diseases. 
Dendrodoa grossularia is a marine algae which 
contains Dendrodoine (3-N,N-dimethylamino-5-indol-
3-oyl-1,2,4-thiadiazole). It possesses a 1,2,4-
thiadiazole unit, a rarity among natural products and it 
has been synthesized1,2. Thiazole analogue of 
dendrodoine derivatives indicates tremendous 
attraction due to their biological and pharmacological 
significance3. Compounds owning to a benzothiazole 
ring have increased the pharmacological interaction 
with a living organism and exhibit anti-inflammatory, 
anti-bacterial4, anti-fungal5 and anti-tumour activity6. 
Methyl-substituted benzothiazole compounds have 
good anti-bacterial and anti-fungal activities7. They 
also have good anti-malarial8 and anti-cancer activity9. 
Based on these facts we decided to develop a new route 
to synthesize, (4-amino-2-(aryl/alkylamino)thiazol-5-
yl)(6-methylbenzo[d] thiazol-2-yl)methanone which 
are hitherto analogues of dendrodoine, by using 6-
methyl bezothiazole in the place of indole ring. From 
this approach, we compare the biological activities of 
various compounds. These novel analogues of 
dendrodoine were retrosynthesized (Scheme I). 
 
 
Scheme I — Retrosynthesis of (4-amino-2-(aryl/alkylamino) 
thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl)methanone 3 





All chemicals and solvents were purchased from 
Merck and Hi-Media with AR grade. The NMR (1H- 
300MHz and 13C NMR-75MHz) spectra were recorded 
on JEOL DRX 300 NMR spectrometer, For FAB mass 
spectra JEOL SX 102/DA-6000 mass spectrometer and 
Nicolet 400D FTIR spectrometer were used. The purity 
of the compounds were checked by TLC using silica gel 
coated on a glass plates. Melting points are determined 
by using digital melting point apparatus and uncorrected. 
All new compounds gave C, H and N analysis (CDRI, 
Lucknow). 
 
General procedure for the synthesis of (4-amino- 
2-(aryl/alkylamino)thiazol-5-yl)(6-methylbenzo 
[d]thiazol-2-yl)methanone 3a-j 
From the literature survey, synthesis of  
2-(2-bromoacetylbenzothiazole obtained from 2-(1-
hydroxyethyl) benzothiazole have been reported by 
Sawhney, Gupta et al.10,11 But in our studies, we have 
attempted to synthesize solution of 2-(2-bromoacetyl-
6-methylbenzothiazole (0.254 g, 1 mmol) obtained 
from 2-(1-hydroxyethyl)-6-methylbenzothiazole in 
DMF (2 mL) was added to the solution of 1-
aryl/alkyl-3-(N-nitroamidino)thiourea 2a-j (1 mmol) 
in DMF (2 mL). The reaction mixture was stirred well 
and added to triethylamine (0.3mL, 2mmol) and 
maintained at the temperature 50-60°C for 15 minutes 
in water bath. It was transferred into ice-cold water 
with constant stirring. The yellow-orange precipitate 
thus obtained. It was filtered, washed with water and 
dried. The crude product was purified and 
recrystallized by using methanol:water in the ratio of 
2:1 to get pure yellow – orange crystalline solid. 
 
Spectral analysis for the synthesized compounds 3a-j 
(4-Amino-2-(phenylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3a: Yield 
60%. m.p. 284–285 °C. Anal.found: C, 58.73; H, 
3.90; N. 15.43%. Calcd. for C18H14N4OS2 (366.46): C, 
58.99; H, 3.85; N, 15.29%. IR (KBr) cm−1 3467, 
3279, 3143 (υ N-H), 3097(aromatic υ C-H), 1630(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) 2.46(s, 3H, CH3), 
7.12(t, 7.35 Hz, 1H, 1ArH), 7.33-7.45(m, 3H, H-5, 
2ArH), 7.72(d, 7.8 Hz, 2H, 2ArH),7.90-8.00(m, 2H, 
H-4, H-7), 8.62(br, 1H, NH), 8.74(br, 1H, NH), 
11.06(s, 1H, NH); FABMS: 367 (MH+). 
(4-Amino-2-(4-chlorophenyl)amino)thiazol-5-yl) 
(6-methylbenzo[d]thiazol-2-yl)methanone, 3b: 
Yield 63%. m.p. 350–353 °C. Anal.found: C, 53.75; 
H, 3.35; N, 13.82%. Calc. for C18H13ClN4OS2 
(400.90): C, 53.92; H, 3.27; N, 13.98%. IR (KBr) 
cm−1 3466, 3279, 3211 (υ N-H), 3066 (aromatic υ C-H), 
1634(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) 2.48(s, 
3H, CH3), 7.39-7.49(m, 3H, H-5, 2ArH), 7.76(d, 8.7 
Hz, 2H, 2ArH), 7.92-8.02(m, 2H, H-4, H-7),8.67(br, 
1H, NH), 8.70(br, 1H, NH), 11.17(s, 1H, NH); 
FABMS: 401 (MH+). 
(4-Amino-2-(4-methoxyphenyl)amino)thiazol-5-
yl)(6-methylbenzo[d]thiazol-2-yl)methanone, 3c: 
Yield 65%. m.p. 264–265°C. Anal.found: C, 57.70; 
H, 4.15; N, 14.34%. Calc. for C19H16N4O2S2 (396.48): 
C, 57.55; H, 4.07; N, 14.13%. IR (KBr) cm−1 3447, 
3265, 3137 (υ N-H), 3083(aromatic υ C-H), 1631(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) δ: 2.47(s, 3H, CH3), 
3.77(s, 3H, OCH3), 6.98(d, 9 Hz, 2H, 2ArH),  
7.42(d, 8.4 Hz, 1H, H-5), 7.58(d, 8.7 Hz, 2H, 2ArH),  
7.90-8.01(m, 2H, H-4, H-7), 8.55(br, 1H, NH), 
8.75(br, 1H, NH), 10.91(s, 1H, NH);13C NMR  
(75 MHz, CDCl3+DMSO-d6) δ: 21.68, 21.72, 96.25, 
114.08, 114.43, 115.00, 121.92, 122.23, 123.80, 
128.49, 132.88, 136.63, 136.72, 151.64, 156.29, 
169.24, 169.98; FABMS: 397 (MH+). 
(4-Amino-2-(4-ethoxyphenyl)amino)thiazol-5-yl) 
(6-methylbenzo[d]thiazol-2-yl)methanone, 3d: 
Yield 68%. m.p. 263–264 °C. Anal. found: C, 58.65; 
H, 4.54; N, 13.36%. Calc. for C20H18N4O2S2 (410.51): 
C, 58.51; H, 4.42; N, 13.65%. IR (KBr) cm−1 3464, 
3277, 3144(υ N-H), 3080(aromatic υ C-H), 1631(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) δ: 1.33(t, 6.9 Hz, 
3H, CH3), 2.47(s, 3H, CH3), 4.02(quart, 6.9 Hz, 2H, 
CH2), 6.96(d, 9 Hz, 2H, 2ArH), 7.41(d, 8.4 Hz, 1H, 
H-5), 7.57(d, 8.7 Hz, 2H, 2ArH), 7.90-7.99(m, 2H,  
H-4, H-7), 8.51(br, 1H, NH), 8.74(br, 1H, NH), 
10.86(s, 1H, NH); FABMS: 411 (MH+). 
(4-Amino-2-(p-tolylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3e: Yield 
60%. m.p. 312–313 °C. Anal. found: C, 59.81;  
H, 4.39; N, 14.57%. Calc. for C19H16N4OS2 (380.48): 
C, 59.97; H, 4.24; N, 14.73%. IR (KBr) cm−1 3461, 
3292, 3130, (υ N-H), 3076, 3080(aromatic υ C-H), 1630 
(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) δ: 2.30(s, 
3H, CH3), 2.48(s, 3H, CH3), 7.20(d, 8.1 Hz, 2H, 
2ArH), 7.43(d, 8.4 Hz, 1H, H-5), 7.58(d, 8.4 Hz, 2H, 
2ArH), 7.92-8.00(m, 2H, H-4, H-7), 8.55(br, 1H, 
NH), 8.71(br, 1H, NH), 10.95(s, 1H, NH); FABMS: 
381 (MH+). 
(4-Amino-2-(ethylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3f: Yield 
68%. m.p. 252–253 °C. Anal. found: C, 52.93; H, 
4.30; N, 17.43%. Calc. for C14H14N4OS2 (318.42): C, 




52.81; H, 4.43; N, 17.60%. IR (KBr) cm−1: 3427(υ N-
H), 2919(aliphatic υ C-H), 1603 (υ C=O); 
1H NMR: 
0.84(t, 7.2 Hz, 3H, CH3), 1.23(s, 3H, CH3), 3.29(br, 
2H, CH2), 7.3-7.4(m, 3H, H-4, H-5, H-7), 8.22(br, 1H, 
NH), 8.25(br, 1H, NH), 8.4 (s, 1H, NH); FABMS: 
319 (MH+). 
 (4-Amino-2-(propylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3g: Yield 
63%. m.p. 275–278 °C. Anal. found: C, 54.01; H, 
4.91; N, 16.92%. Calc. for C15H16N4OS2 (332.45): C, 
54.19; H, 4.85; N, 16.85%. IR (KBr) cm−1 : 3428(υ N-
H), 2920, (aliphatic υ C-H), 1688(υ C=O); 
1H NMR: 
(300 MHz, DMSO-d6) 1.22(s, 3H, CH3), 2.2(t, 
7.2Hz,3H, CH3) 2.26-2.35(sext,7.3Hz, 2H, CH2), 
4.24(quart, 7.4Hz, 2H, CH2), 7.33-7.45(m, 3H, H-4, 
H-5, H-7), 8.07(br, 1H, NH), 8.25(br, 1H, NH), 8.31 
(s, 1H, NH); FABMS: 333 (MH+). 
(4-Amino-2-(isopropylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3h: Yield 
60%. m.p. 232–233 °C. Anal. found: C, 54.46; H, 4.34; 
N, 17.21%. Calc. for C15H16N4OS2 (332.45): C, 54.19; 
H, 4.85; N, 16.85%. IR (KBr) cm−1: 3341(υ N-H), 3042, 
(aromatic υ C-H), 1648 (υ C=O); 
1H NMR: (300 MHz, 
DMSO-d6) 1.18(d, 6.6Hz, 6H, 2CH3), 2.5(s, 3H, CH3), 
4.24(quart, 6.6Hz, 1H, CH), 7.96-8.07(m, 3H, H-4, H-5, 
H-7), 8.47(br, 1H, NH),8.64(br, 1H, NH), 10.17(s, 1H, 
NH); FABMS: 333 (MH+). 
(4-Amino-2-(butylamino)thiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3i: Yield 
66%. m.p. 219–220 °C. Anal. found: C, 55.36; H, 5.28; 
N, 16.23%. Calc. for C16H18N4OS2 (346.47): C, 55.47; 
H, 5.24; N, 16.17%. IR (KBr) cm−1 : 3427(υ N-H), 
1605(υ C=O); 
1H NMR: (300 MHz, DMSO-d6) 1.2(t, 7.2 
Hz, 3H, CH3), 2.1(sext, 6.9 Hz, 2H, CH2), 2.74(quint, 
7.2 Hz, 2H, CH2), 3.34(br, 2H, CH2),7.48-8.14(m, 3H, 
H-4, H-5, H-7 ), 8.57(br, 1H, NH), 8.78(br, 1H, 
NH),10.92(s, 1H, NH);FABMS: 347 (MH+). 
(2-(Allylamino)-4-aminothiazol-5-yl)(6-
methylbenzo[d]thiazol-2-yl)methanone, 3j: Yield 
68%. m.p. 212–213 °C. Anal. found: C, 54.12; H, 
4.82; N, 16.92%; Calc. for C15H14N4OS2 (330.43): C, 
54.52; H, 4.27; N, 16.96%. IR (KBr) cm−1 : 3447(υ N-
H), 2918(aliphatic υ C-H), 1604(υ C=O); 
1H NMR: 
(300 MHz, DMSO-d6) 0.84(d, 7.3Hz, 2H, CH2), 
2.15(s, 3H, CH3), 2.26-2.34(m, 1H, CH), 2.52(d, 6.6 
Hz,CH2), 7.3-7.6(m, 3H, H-4,H-5,H-7), 8.62(br, 1H, 
NH), 8.72(br, 1H, NH), 9.13(s, 1H, NH).; FABMS: 
331 (MH+). 
 
Results and Discussion 
Chemistry 
The synthesis of (4-amino-2-(aryl/alkylamino) 
thiazol-5-yl)(6-methylbenzo[d]thiazol-2yl)methanone 
3a–j which are novel analogues of the cytotoxic 
marine alkaloid dendrodoine, is similar to that 
reported by Yardily et al.12 But in this studies instead 
of 2-(2-bromoacetyl)benzothiazole we used 2-(2-
bromoacetyl)-6-methylbenzothiazole (Scheme II). For 
this, [4+1] hetero cyclization reaction was used, 
during which thiourea derivatives gave 4 ring atoms 
for the construction of a thiazole, consequently acting 
as [C-N-C-S] synthons13-15. The other one carbon 
(C-5) of the thiazole was sourced from 2-(2-
bromoacetyl)-6-methylbenzothiazole 2. A mixture of 
2 in dimethylformamide (DMF) and 1-aryl/alkyl-3-
(N-nitroamidino)thiourea 1 (Table I) in DMF was 
taken. The reaction mixture was stirred well and 
triethylamine was added and heated on a water bath at 
50–60°C for 15 minutes. This led to a higher yield of 
the desired products, 3a–j. The structures of all these 
compounds 3a–j were elucidated from their spectral 
data (IR, 1H-NMR and MS) and elemental analysis.  
 
Scheme II — Synthetic route for the formation of benzothiazole derivatives 3a-j 
Table I — (4-amino-2-(aryl/alkylamino)thiazol-5-yl) 
(6-methylbenzo[d]thiazol-2-yl)methanone 3a–j 
Compd Substituent Compd Substituent 
3a Phenyl 3f Ethyl 
3b 4-chlorophenyl 3g n-propyl 
3c 4-methoxyphenyl 3h iso-propyl 
3d 4-ethoxyphenyl 3i n-butyl 
3e 4-tolyl 3j Allyl- 




A mixture of 1-(4-chlorophenyl)-3-N-nitroamidino) 
thiourea (1 mmol) in DMF (2 mL), 2-(2-
bromoacetyl)-6-methylbenzothiazole 2 in DMF (2 
mL) was taken. The reaction mixture was heated on a 
water bath at 80–85°C for 5 min. To this, 
triethylamine (0.15 mL, 1 mmol) was added and the 
mixture was continuously heated along with stirring. 
The yellow crystalline compound was obtained. It 
was filtered, washed by using water and dried. The 
crude material was recrystallized by using 
methanol:water (2:1). Elemental analysis confirmed 
the molecular formula of the compound as 
C18H13ClN4OS2. Its IR (KBr) spectrum showed bands 
at 3466, 3279 and 3211 cm-1 which are assigned as 
secondary amine stretching. The absorption band at 
3066cm-1 can be attributed to aromatic C-H stretching 
vibration. The conjugated carbonyl group gives rise to 
a vibrational frequency at 1634 cm-1. The 1H-NMR 
(300 MHz, DMSO-d6) spectrum showed, the methyl 
group produces a three - hydrogen singlet at δ 2.48. 
The multiplet at δ 7.39-7.49 has been attributed to H-
5 of the 6-methylbenzothiazole and other two 
aromatic hydrogens. The two hydrogen doublet δ 7.76 
arises from the two aromatic hydrogens. The H-4 and 
H-7 of the 6-methylbenzothiazole ring appear as a 
multiplet at δ 7.92-8.02. The two 4-amino hydrogens 
appear as two well separated broad singlets at δ 8.67 
and 8.70. It is due to the two hydrogens are not 
exchanging rapidly on the chemical shift time scale 
and they are in two different chemical environments. 
The presence of NH hydrogen of the NHAr group is 
seen at δ 11.17 as a one hydrogen singlet The Mass 
spectrum showed a strong MH+ peak at m/z 401, 
which confirmed the molecular mass of the 
compound. From the above evidences, the compound 
was found to be (4-amino-2-(4-chlorophenyl) 
amino)thiazol-5-yl)(6-methylbenzo[d]thiazol-2-yl) 
methanone 3b. 
In Scheme III, the leaving group could be NH2NO2 
group. Thus the required thiourea derivative provide 
the C-N-C-S atoms that go to the making of the 
thiazole ring. The remaining C-5 atom would come 
from α-haloketone with benzothiazole. In this reaction 




To assess the bioactivity, the benzothiazoles 3a–j 
were screened against the bacterial strains Klebsiella 
pneumoniae(MTCC 7407), Pseudomonas aeruginosa 
(MTCC 6538), Salmonella typhi (MTCC 733), 
Bacillus subtilis(MTCC 1134), Streptococcus mutans 
(MTCC 1936) and Staphylococcus aureus (MTCC 
916) by using disc diffusion method16. 
For evaluating the antibacterial activity Penicillin 
G was used as the reference drug. Amongst the 
compounds tested for antibacterial activity, all the 
compounds showed moderate activity (Table II). 
 
Anti-oxidant Assay (DPPH Free Radical-
Scavenging activity) 
The free radical scavenging activity of the 
compounds were determined by using 1,1-Diphenyl-
2-picryl-hydrazyl (DPPH). DPPH 1 mg in 10-5 mol 
methanol was prepared in a 250-ml standard flask 
 
Scheme III — Mechanistic pathway of the reaction 3a-j 




(control – 2.8 mL of this solution + 0.05 mL 
methanol). Benzothiazole solutions of different 
concentrations (0.1, 0.25, 0.5, 0.75, 1 mM) were 
prepared. BHA (standard) solutions of different 
concentrations (0.1, 0.25, 0.5, 0.75, 1 mM) were also 
prepared. The absorbance values of the control, test 
and standard solutions were recorded at 517 nm. From 
the absorbance values, % of inhibition was calculated. 
Then the % of inhibition was plotted against 
concentrations for different samples as well as BHA. 
From the graph, IC50 values were calculated. The 
IC50values are lesser, higher the antioxidant capacity 
of the compounds. For each compound, five 
concentrations were employed and the Percentage 
inhibition was determined. The percentage inhibition 




The compound 3d with group ethoxyphenyl 
showed very good activity compared to butylated 
hydroxyl anisole (BHA) at all the concentrations 
tested (Figure 1). 
 
DNA cleavage activity 
A number of studies have shown that the clinical 
efficacy of many drugs correlates with their ability to 
induce enzyme-mediated DNA cleavage. The 
inhibitory potency of the test compounds was 
assessed by comparing their potential for cleaving 
DNA with that of the control. Gel electrophoresis was 
used for the analysis of 3a, 3b, 3c, 3d, 3e and  
3h having the groups phenyl, chlorophenyl, 
methoxyphenyl, ethoxyphenyl, methylphenyl and 
isopropyl respectively 
The compounds were added separately to the calf 
thymus DNA sample. The sample mixtures were 
incubated at 37°C for 2 h and subjected to gel 
electrophoresis. Three hundred milligrams of agarose 
was dissolved in 25 mL of TAE buffer (4.84 g  
Tris base, pH 8.0, 0.5 M EDTA/1 L) by boiling.  
At ~55°C, the gel was poured into the gel  
cassette fitted with comb and allowed to solidify.  
The comb was removed and the gel placed in the 
electrophoresis chamber flooded with TAE buffer. 
The DNA samples (mixed with bromophenol blue dye 
at 1:1 ratio) were loaded carefully into the wells, 
along with standard DNA marker and a constant 
electricity of 100 V was maintained until the dye front 
reached the end of the gel. Then the gel was removed 
and stained with ETBR solution (10 μg/mL) for 10–
15 min, and the bands observed under a UV 
transilluminator. 
Results showed that the compounds 3a and 3b 
completely cleaved the DNA. The compounds 3e & 
3h partially cleaved the DNA and the other samples 
were ineffective (Figure 2). 
Table II — Anti-bacterial activity of compounds 3a–j 



















3a 11 9 8 8 8 9 
3b 13 11 10 13 14 12 
3c 8 9 11 9 9 10 
3d 9 10 11 9 9 8 
3e 9 10 10 9 8 10 
3f 8 8 9 8 8 8 
3g 8 9 8 8 9 10 
3h 9 9 9 8 8 8 
3i 9 8 8 10 8 8 
3j 8 9 8 9 9 8 
Penicillin G 15 15 17 18 15 16 
 
Figure 1 — Antioxidant activity of compounds 3a–j 
 




Anti-proliferative activity  
The two benzothiazole compounds were screened 
for their anti-proliferative activity against the breast 
cancer cell line MCF-7 by the MTT method and IC50 
values calculated. For evaluating the anti-proliferative 
activity, compound 3b was the most active derivative 
against the breast cancer cell line, with an IC50 value 
of 10 µg/mL. The compound 3d showed IC50 of > 
100µg/mL. 
 
Molecular Docking Studies 
Molecular docking is a well-established and 
regularly used approach in drug design. This studies 
were carried out to investigate the binding affinities of 
newly synthesized titled compounds and the protein 
receptor of Klebsiella Pneumonia(PDB code:5O77), 
which is downloaded from protein data bank in PDB 
format. K. Pneumonia (Bacteria), most commonly 
causes pneumonia and form broncho pneumonia and 
bronchitis in living beings. It is a gram-negative, 
encapsulated, non-motile bacterium that is found in 
the environment and has been associated with 
pneumonia in the alcoholic and diabetic patient 
population. The bacterium typically settles human 
mucosal surfaces of the oropharynx and 
gastrointestinal (GI) tract. Once the bacterium enters 
the body, it can show high degrees of virulence and 
antibiotic resistance17. 
The above synthesized compounds 3b, 3c, 3g, 3i 
were docked with 5O77 receptor (inhibitor of KP) 
(Figure 3, Figure 4, Figure 5 and Figure 6) using Hex 
dock software and visualized by Discovery studio  




Figure 2 — DNA cleavage study of compounds 
 
Figure 3 — 3D and 2D interaction of the compound 3b and the protein 5O77 
 
 
Figure 4 — 3D and 2D interaction of the compound 3c with the protein receptor 5O77 











Figure 6 — 3D and 2D interaction of the compound 3i with the protein receptor 5O77 
 
Table III — LIPINSKI rule of five for the compounds 
Compd Mol. Wt < 500 Dalton HB donor<5 HB acceptor <10 Log P <5 Mol. Refractivity 40-130 
3b 400.50 3 5 5 109.05 
3c 396.00 3 6 4.62 110.59 
3g 332.00 3 5 3.69 93.09 
3i 346.00 3 5 4.086 97.71 
 
 




Active sites of interactions 
π-σ interactions π-cation interactions π-π interactions Electrostatic Van der Waals 
3b −331.03 LYS A73 ASG A159 − ARG A159, ASN A128, 
ARG A126, ARG A75. 
ARG A93, ASP A120 
LYS A73, ASP A 158, 
THR A119, THR A74. 
3c −339.87 − LYSA16, ARG A38. − TYR A36, VAL A 109, 
TYR A304 
VAL A18, VAL A334, 
GLN A336, TYR A296.  
3g −300.88 − LYS A73, LYS A16 − ASN A60, GLU A20, 
ARG A38 
ASP A 62, MET A61, 
SER A64, Lys A16 
3i −307.40 − LYS A73, LYS A16 TYR A36, LYS 
A73 
TYR A36, LYS A16, 
GLU A110, ARG A38 
TRP A294 
 
LIPINSKI rule of five for drug ability (Table III). The 
binding energy and interacting sites are tabulated 
(Table IV). The stability of the ligand-receptor 
arrangement was  understood  by  hydrogen  bonding, 
electrostatic and covalent interactions18. Lower the 
binding energy, higher will be the protein-ligand 
interaction and more antibacterial activity19. This 
study shows that the antibacterial activity of the 
methoxy substituted compound 3c has more binding 
interaction with the protein (5O77).  





The objectives of the present study were to 
synthesize novel benzothiazoles with the hope of 
discovering new structure leads serving as anti-
bacterial, anti-oxidant, DNA cleavage and anti-
proliferative agents. These compounds exhibited 
significant activity against the growth of bacteria. 
The results of the anti-bacterial studies revealed that 
the compounds 3a-j were moderately active. The 
compound 3b was found to exhibit very good anti-
proliferative agent against the breast cancer cell line, 
MCF-7 and its IC50 value was 10 µg/mL. These 
results were further substantiated by the DNA 
cleavage and antioxidant property of these 
compounds. The test compounds 3a and 3b  
cleaved DNA completely. The compound 3d 
revealed potent anti-oxidant activity when compared 
with BHA. The molecular docking suggests that, 
compounds-receptor systems are stabilized by  
π-cation, electrostatic and van der Waals 
interactions. Thus the study confirms the 
methylbenzothiazole with various substituents on 
aminothiazole ring could be usable as a 
antiproliferative drug in the future. 
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